DK3010506T3 - Pridopidin i behandling af huntingtons sygdom - Google Patents
Pridopidin i behandling af huntingtons sygdom Download PDFInfo
- Publication number
- DK3010506T3 DK3010506T3 DK14813621.1T DK14813621T DK3010506T3 DK 3010506 T3 DK3010506 T3 DK 3010506T3 DK 14813621 T DK14813621 T DK 14813621T DK 3010506 T3 DK3010506 T3 DK 3010506T3
- Authority
- DK
- Denmark
- Prior art keywords
- pridopidine
- huntington
- disease
- treatment
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title 1
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title 1
- 229950003764 pridopidine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837928P | 2013-06-21 | 2013-06-21 | |
| US201361877832P | 2013-09-13 | 2013-09-13 | |
| PCT/US2014/043204 WO2014205229A1 (en) | 2013-06-21 | 2014-06-19 | Use of high dose pridopidine for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3010506T3 true DK3010506T3 (da) | 2021-07-12 |
Family
ID=52105289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14813621.1T DK3010506T3 (da) | 2013-06-21 | 2014-06-19 | Pridopidin i behandling af huntingtons sygdom |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US10322119B2 (da) |
| EP (1) | EP3010506B1 (da) |
| JP (1) | JP2016523862A (da) |
| KR (1) | KR102316933B1 (da) |
| CN (1) | CN105592848A (da) |
| AU (1) | AU2014281414A1 (da) |
| BR (1) | BR112015029918A2 (da) |
| CA (1) | CA2913781C (da) |
| CL (1) | CL2015003690A1 (da) |
| DK (1) | DK3010506T3 (da) |
| EA (1) | EA201690069A1 (da) |
| ES (1) | ES2879631T3 (da) |
| HK (1) | HK1221646A1 (da) |
| HU (1) | HUE054783T2 (da) |
| IL (1) | IL242804B (da) |
| MX (1) | MX384234B (da) |
| PE (2) | PE20160195A1 (da) |
| PH (1) | PH12015502691A1 (da) |
| PL (1) | PL3010506T3 (da) |
| SG (1) | SG11201509729YA (da) |
| TW (1) | TW201529069A (da) |
| UA (1) | UA122999C2 (da) |
| UY (1) | UY35624A (da) |
| WO (1) | WO2014205229A1 (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| PE20161220A1 (es) * | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| PL3261721T3 (pl) * | 2015-02-25 | 2022-12-27 | Prilenia Neurotherapeutics Ltd. | Stososowanie pridopidyny w celu poprawy pamięci |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| US20170020854A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| WO2017147366A1 (en) | 2016-02-24 | 2017-08-31 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| PT3504187T (pt) | 2016-08-24 | 2025-05-09 | Prilenia Neurotherapeutics Ltd | Utilização da pridopidina no tratamento do declínio funcional |
| DK3503890T3 (da) * | 2016-08-24 | 2025-01-27 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af dystonier |
| CN109952100A (zh) | 2016-09-15 | 2019-06-28 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗焦虑和抑郁的用途 |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| PL3512506T3 (pl) | 2016-09-16 | 2022-05-30 | Prilenia Neurotherapeutics Ltd. | Zastosowanie pridopidyny w leczeniu zespołu retta |
| IL268125B2 (en) | 2017-01-20 | 2023-04-01 | Prilenia Neurotherapeutics Ltd | Pridopidine for the treatment of fragile x syndrome |
| ES2938546T3 (es) | 2017-08-14 | 2023-04-12 | Prilenia Neurotherapeutics Ltd | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina |
| CN111278431A (zh) | 2017-08-30 | 2020-06-12 | 普瑞尼亚神经治疗有限公司 | 普利多匹定的高浓度剂型 |
| CN111343982A (zh) | 2017-09-08 | 2020-06-26 | 普瑞尼亚神经治疗有限公司 | 用于治疗药物诱发的异动症的普利多匹定 |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| CN113365551A (zh) * | 2019-01-31 | 2021-09-07 | 豪夫迈·罗氏有限公司 | 评估亨廷顿氏病的进展 |
| CA3125893C (en) | 2019-02-04 | 2024-03-19 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism |
| BR112021024744A2 (pt) * | 2019-06-12 | 2022-03-22 | Prilenia Neurotherapeutics Ltd | Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington |
| JP7432711B2 (ja) * | 2019-09-17 | 2024-02-16 | エフ． ホフマン－ラ ロシュ アーゲー | 動作障害患者に対する個別化医療の改善 |
| US20230390232A1 (en) * | 2020-10-28 | 2023-12-07 | Buck Institute For Research On Aging | N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| WO2005053703A1 (en) | 2003-12-02 | 2005-06-16 | Leslie James Sheldon | Combination therapy for dementia, depression and apathy |
| JP4891908B2 (ja) | 2004-10-13 | 2012-03-07 | エヌエスエービー，フィリアル アフ ニューロサーチ スウェーデン アクチボラゲット，スヴェリエ | ４−（３−メタンスルホニルフェニル）−１−ｎ−プロピルピペリジンの合成方法 |
| EP1815857A1 (en) * | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| PT2146961E (pt) | 2007-04-12 | 2014-04-30 | Ivax Int Gmbh | Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados |
| US8669048B2 (en) | 2008-06-24 | 2014-03-11 | Parkinson's Institute | Pluripotent cell lines and methods of use thereof |
| US8384755B2 (en) | 2009-08-26 | 2013-02-26 | Intouch Technologies, Inc. | Portable remote presence robot |
| US20110206782A1 (en) | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| NZ608120A (en) | 2010-09-03 | 2014-12-24 | Ivax Int Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US9006445B2 (en) | 2011-09-07 | 2015-04-14 | IVAX International GmbH | Polymorphic form of pridopidine hydrochloride |
| US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| NZ630560A (en) | 2012-04-04 | 2016-11-25 | Teva Pharmaceuticals Int Gmbh | Pharmaceutical compositions for combination therapy |
| EP2900226A4 (en) | 2012-09-27 | 2016-03-30 | Teva Pharma | COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE |
| CA2884781A1 (en) | 2012-09-27 | 2014-04-03 | Teva Pharmaceutical Industries Ltd. | Laquinimod and pridopidine for treating neurodegenerative disorders |
| PE20161220A1 (es) | 2014-01-22 | 2016-11-23 | Teva Pharmaceuticals Int Gmbh | Formulaciones de pridopidina de liberacion modificada |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| PL3261721T3 (pl) | 2015-02-25 | 2022-12-27 | Prilenia Neurotherapeutics Ltd. | Stososowanie pridopidyny w celu poprawy pamięci |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017048457A1 (en) | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| PT3504187T (pt) * | 2016-08-24 | 2025-05-09 | Prilenia Neurotherapeutics Ltd | Utilização da pridopidina no tratamento do declínio funcional |
| DK3503890T3 (da) | 2016-08-24 | 2025-01-27 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af dystonier |
| CN109952100A (zh) | 2016-09-15 | 2019-06-28 | 普瑞尼亚医疗发展有限公司 | 普利多匹定用于治疗焦虑和抑郁的用途 |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| PL3512506T3 (pl) | 2016-09-16 | 2022-05-30 | Prilenia Neurotherapeutics Ltd. | Zastosowanie pridopidyny w leczeniu zespołu retta |
-
2014
- 2014-06-19 ES ES14813621T patent/ES2879631T3/es active Active
- 2014-06-19 US US14/309,111 patent/US10322119B2/en active Active
- 2014-06-19 DK DK14813621.1T patent/DK3010506T3/da active
- 2014-06-19 CA CA2913781A patent/CA2913781C/en active Active
- 2014-06-19 PE PE2015002618A patent/PE20160195A1/es not_active Application Discontinuation
- 2014-06-19 MX MX2015017307A patent/MX384234B/es unknown
- 2014-06-19 PE PE2016002253A patent/PE20170302A1/es not_active Application Discontinuation
- 2014-06-19 PL PL14813621T patent/PL3010506T3/pl unknown
- 2014-06-19 WO PCT/US2014/043204 patent/WO2014205229A1/en not_active Ceased
- 2014-06-19 UA UAA201600462A patent/UA122999C2/uk unknown
- 2014-06-19 AU AU2014281414A patent/AU2014281414A1/en not_active Abandoned
- 2014-06-19 HK HK16109788.9A patent/HK1221646A1/zh unknown
- 2014-06-19 EP EP14813621.1A patent/EP3010506B1/en active Active
- 2014-06-19 JP JP2016521580A patent/JP2016523862A/ja not_active Withdrawn
- 2014-06-19 CN CN201480035525.7A patent/CN105592848A/zh active Pending
- 2014-06-19 BR BR112015029918A patent/BR112015029918A2/pt not_active Application Discontinuation
- 2014-06-19 HU HUE14813621A patent/HUE054783T2/hu unknown
- 2014-06-19 SG SG11201509729YA patent/SG11201509729YA/en unknown
- 2014-06-19 EA EA201690069A patent/EA201690069A1/ru unknown
- 2014-06-19 KR KR1020167001531A patent/KR102316933B1/ko active Active
- 2014-06-20 TW TW103121433A patent/TW201529069A/zh unknown
- 2014-06-23 UY UY35624A patent/UY35624A/es not_active Application Discontinuation
-
2015
- 2015-11-26 IL IL242804A patent/IL242804B/en unknown
- 2015-12-02 PH PH12015502691A patent/PH12015502691A1/en unknown
- 2015-12-21 CL CL2015003690A patent/CL2015003690A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3010506B1 (en) | 2021-05-12 |
| PE20160195A1 (es) | 2016-05-14 |
| PE20170302A1 (es) | 2017-03-31 |
| EP3010506A1 (en) | 2016-04-27 |
| EP3010506A4 (en) | 2017-02-08 |
| JP2016523862A (ja) | 2016-08-12 |
| CA2913781A1 (en) | 2014-12-24 |
| KR102316933B1 (ko) | 2021-10-26 |
| KR20160055122A (ko) | 2016-05-17 |
| SG11201509729YA (en) | 2015-12-30 |
| MX2015017307A (es) | 2016-08-03 |
| CN105592848A (zh) | 2016-05-18 |
| HUE054783T2 (hu) | 2021-09-28 |
| TW201529069A (zh) | 2015-08-01 |
| BR112015029918A2 (pt) | 2017-07-25 |
| WO2014205229A8 (en) | 2015-04-09 |
| US10322119B2 (en) | 2019-06-18 |
| AU2014281414A1 (en) | 2016-01-21 |
| UY35624A (es) | 2015-01-30 |
| HK1221646A1 (zh) | 2017-06-09 |
| US20140378508A1 (en) | 2014-12-25 |
| ES2879631T3 (es) | 2021-11-22 |
| EA201690069A1 (ru) | 2016-06-30 |
| CA2913781C (en) | 2022-05-10 |
| PL3010506T3 (pl) | 2021-11-02 |
| WO2014205229A1 (en) | 2014-12-24 |
| CL2015003690A1 (es) | 2016-10-28 |
| UA122999C2 (uk) | 2021-02-03 |
| IL242804B (en) | 2022-02-01 |
| MX384234B (es) | 2025-03-14 |
| PH12015502691A1 (en) | 2016-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3010506T3 (da) | Pridopidin i behandling af huntingtons sygdom | |
| LTC3057969I2 (lt) | Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su kit | |
| EP2956047A4 (en) | IRIS EXPANDER | |
| UA29014S (uk) | Комп'ютер | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| IL240845A0 (en) | Compounds and uses thereof for the modulation of hemoglobin | |
| FR3007626B1 (fr) | Sous-vetement tricote elastique masculin | |
| EP2968137A4 (en) | EMULSION FORMULATIONS | |
| EP2974462A4 (en) | CLOUD-BASED CONNECTIVITY | |
| EP2997047A4 (en) | heparansulphates | |
| IL242293B (en) | Bacteriophage therapy | |
| EP3004181A4 (en) | heparan sulfate | |
| FR3004424B1 (fr) | Marchepied amovible d'aeronef, et aeronef | |
| EP2957581A4 (en) | Organopolysiloxane GRAFT POLYMER | |
| EP2989568A4 (en) | DETERMINING THE IMPORTANCE OF ATTRIBUTES | |
| EP2933303A4 (en) | EMULSIONSKOAGULANS | |
| FR3005989B1 (fr) | Turbopropulseur d'aeronef | |
| EP2945986A4 (en) | VENTILATED TALCUM AND RELATED METHODS | |
| ES1094985Y (es) | Mini-moto infantil | |
| UA27219S (uk) | Форматор-вулканізатор 75" та 88" | |
| UA27190S (uk) | Ванна дитяча | |
| UA27582S (uk) | Лист ресори | |
| ES1092430Y (es) | "Anafe paellero" | |
| ES1084105Y (es) | "Conjunto de calzado" |